BeStock  
Stocks › IOVA

Iovance Biotherapeutics IOVA

US equityMarket cap rank #2386
$6.90 −$0.41 (-5.61%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $6.99 +1.25%
Open$7.17
Prev close$7.31
Day range$6.77 – $7.40
Volume13.73M
Market cap$3.19B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership62.9%-0.94 pts vs. prior quarter
Institutions holding369+33 vs. prior quarter
Insider trades (recent)30 buys / 20 sellsNet buying
Short interest14.39% of floatDays to cover 4.2 · as of 30 Oct 2026
Short-sale volume share16.7%5-day average of daily volume

Short-sale volume as % of daily volume

8%15%21%27%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$23.78M (7 inflow days, 13 outflow days).

Net flow by order size, last 20 sessions

−$5.4MSuper−$18.4MBig−$6.3MMid+$18.9MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 29.3% of shares outstanding.

Largest holders

  • BlackRock8.19%
  • MHR Fund Management LLC6.26%
  • Wayne Rothbaum6.07%
  • State Street Global Advisors4.69%
  • Two Sigma Investments, LP4.11%
  • Vanguard Capital Management, LLC3.98%
  • Vanguard Portfolio Management, LLC2.65%
  • Geode Capital Management, LLC2.26%

By investor type

  • Mutual Fund36.67%
  • Hedge Fund11.91%
  • Individual/Insider6.42%
  • VC/PE Fund6.26%
  • Public Company4.18%
  • Private Company2.70%
  • Insurance Company0.81%
  • Government Pension Fund0.32%

Reported short interest has fallen from 22.73% to 14.39% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Van Eck Associates Corporation Mutual Fund 2026/Q3 +184,099 0.0%
UBS Asset Management Mutual Fund 2026/Q3 +1,259,960 0.7%
BlackRock Mutual Fund 2026/Q3 +946,279 8.2%
Rhenman & Partners Asset Management AB Hedge Fund 2026/Q3 +797,250 0.5%
Barclays PLC Public Company 2026/Q3 +407,497 0.1%
Pictet Asset Management Limited Mutual Fund 2026/Q3 +373,491 0.1%
FMR Mutual Fund 2026/Q3 +353,918 0.4%
Russell Investment Management, LLC Mutual Fund 2026/Q3 +319,979 0.1%
Renaissance Technologies Corp. Hedge Fund 2026/Q3 +257,700 0.1%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +192,458 4.0%
Tema ETFs LLC Mutual Fund 2026/Q3 +187,428 0.1%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +2,578,238 0.8%
State Street Global Advisors Mutual Fund 2026/Q3 +7,030,160 5.4%
BlackRock Mutual Fund 2026/Q3 +5,877,176 8.2%
Two Sigma Investments, LP Hedge Fund 2026/Q3 +5,323,264 4.1%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
10 Nov 2026 Frederick Vogt Interim CEO, President, General Counsel, Corporate Secretary & Director Derivative Exercise and Sale -191,303 $8.09 604,144
10 Nov 2026 Frederick Vogt Interim CEO, President, General Counsel, Corporate Secretary & Director Derivative Exercise and Retained +8,697 $7.55 604,144
9 Nov 2026 Daniel Kirby Chief Commercial Officer Derivative Exercise and Sale -3,935 $8.08 160,576
9 Nov 2026 Daniel Kirby Chief Commercial Officer Derivative Exercise and Retained +6,065 – 160,576
5 Nov 2026 Corleen Roche Chief Financial Officer Derivative Exercise and Sale -5,311 $8.04 35,946
5 Nov 2026 Corleen Roche Chief Financial Officer Derivative Exercise and Retained +7,189 – 35,946
29 Sep 2026 Noah Berkowitz Chief Medical Officer Other Derivative Acquisition +135,000 $14.82 135,000
29 Sep 2026 Noah Berkowitz Chief Medical Officer Other Derivative Acquisition +180,000 – 180,000
7 Sep 2026 Igor Bilinsky Chief Operating Officer Derivative Exercise and Sale -3,976 $8.70 142,074
7 Sep 2026 Igor Bilinsky Chief Operating Officer Derivative Exercise and Retained +3,837 – 142,074
7 Sep 2026 Frederick Vogt Interim CEO, President, General Counsel, Corporate Secretary & Director Derivative Exercise and Sale -6,638 $8.70 595,447
7 Sep 2026 Frederick Vogt Interim CEO, President, General Counsel, Corporate Secretary & Director Derivative Exercise and Retained +8,988 – 595,447
7 Sep 2026 Raj Puri Chief Regulatory Officer Derivative Exercise and Sale -4,478 $8.70 256,364
7 Sep 2026 Raj Puri Chief Regulatory Officer Derivative Exercise and Retained +5,288 – 256,364
31 Aug 2026 Igor Bilinsky Chief Operating Officer Derivative Exercise and Sale -4,472 $8.28 138,237
31 Aug 2026 Igor Bilinsky Chief Operating Officer Derivative Exercise and Retained +4,317 – 138,237
31 Aug 2026 Frederick Vogt Interim CEO, President, General Counsel, Corporate Secretary & Director Derivative Exercise and Sale -17,702 $8.28 586,459
31 Aug 2026 Frederick Vogt Interim CEO, President, General Counsel, Corporate Secretary & Director Derivative Exercise and Retained +23,967 – 586,459
31 Aug 2026 Raj Puri Chief Regulatory Officer Derivative Exercise and Sale -2,508 $8.28 251,076
31 Aug 2026 Raj Puri Chief Regulatory Officer Derivative Exercise and Retained +2,962 – 251,076

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 65,189,660 14.4% 4.2
15 Oct 2026 58,925,298 13.0% 4.4
30 Sep 2026 64,827,030 14.3% 2.8
15 Sep 2026 87,127,871 19.2% 7.4
31 Aug 2026 88,138,991 19.5% 5.3
14 Aug 2026 102,940,590 22.7% 4.8

Discussion

No comments yet — be the first to weigh in on IOVA.

Sign in to join the discussion.

Scroll to Top